Peramivir News

Latest Peramivir News

Sat, 31 Jul 2010 11:47:01 +0200

Peramivir News updated every 15 minutes. Stay informed on latest Peramivir Avian Influenza H5N1 News.

Influenza Viruses killed by Ultraviolet Air Purifiers

Sat, 31 Jul 2010 11:47:01 +0200

A main cause of influenza is through inhalation of virus particles that are spread by sick people coughing and sneezing. During a pandemic flu one of the few ways to reduce the risk of spread to yourself or others is to trap the virus particles with a specialized air purifier that is equipped with an ultraviolet light. As the virus is drawn into the purifier the ultraviolet light kills it. Find out more about ultraviolet air purifiers ...

BioCryst 1Q loss narrows on peramivir revenue

Wed, 28 Apr 2010 17:31:48 +0200

BioCryst Pharmaceuticals Inc. said Wednesday its first-quarter loss narrowed on a boost in flu treatment-related revenue.

Peramivir Emergency Use Authorization Disposition Letter and Question and Answer Attachment

Wed, 14 Oct 2009 08:58:00 +0200

This letter responds to your request regarding the disposition of peramivir upon termination of the authorization of emergency use that was issued on October 23, 2009, pursuant to section 564 of the Federal Food, Drug, and Cosmetic Act , 21 U.S.C. A A 360bbb-3. Attached are Questions and Answers Regarding Termination of the Emergency Use ...

St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection.

BioCryst Says Study Confirms and Extends Evidence Seen in a Previous Study BIRMINGHAM, Ala., May 2 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that investigators at St. Jude Children's Research Hospital, Memphis, TN, reported favorable results evaluating peramivir ...

Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections.

BIRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assistant Professor, ...

BioCryst's Partner Shionogi Files for Peramivir Regulatory Approval in Japan.

BIRMINGHAM, Ala., Nov. 4 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi and amp; Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a ...

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference.

Pharmacokinetic and Safety Profile of the Intramuscular Formulation of Peramivir Supports Further Evaluation as Treatment for Acute Influenza BIRMINGHAM, Ala., June 18 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. presented results from two Phase I clinical studies of an intramuscular ...

BioCryst Announces Two Additional Peramivir Partnerships.

BIRMINGHAM, Ala., Jan. 11 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed agreements with two additional partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities for territories ...

BioCryst Announces Presentation of Peramivir Human Clinical Data at the 46th Annual ICAAC Meeting.

Injectable Peramivir Performs Well in Phase I Safety Trials BIRMINGHAM, Ala., Sept. 29 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today reported positive results from several Phase I safety and pharmacokinetic studies with the neuraminidase inhibitor, peramivir, in development for the ...

BioCryst Updates Peramivir Clinical Development Plan.

BIRMINGHAM, Ala., Jan. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today provided an update on activities conducted following release of the preliminary Phase II data and outlined the resulting clinical development plan for intramuscular (i.m.) peramivir. (Logo: ...

BioCryst Receives First Peramivir Order From U.S. Government.

BIRMINGHAM, Ala., Nov. 5 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced it has received an initial order for 10,000 courses of intravenous (i.v.) peramivir (600 mg once-daily for five days) with a value of $22.5 million under a newly issued contract with the Department of ...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results.

BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its inventory of ...

COLD-fX : "Impressive" concludes leading American cold/flu experts in new U.S. scientific report

Sat, 31 Jul 2010 11:47:01 +0200

A major U.S. scientific review (monograph) of COLD-fX conducted by leading American cold/flu experts concludes the cold/flu remedy delivered "impressive" benefits to users.
COLD-fX is the result of intensive scientific research on a natural herb, American ginseng root. It is believed to be the first natural medicine in Canada approved to fight colds and flu by boosting the immune system. In the United States, COLD-fX is classified and regulated as a dietary supplement.
Many of the world's top athletes rely on COLD-fX to strengthen their immune systems, prepare for the rigors of training, and protect themselves against everyday stresses. Find out more about COLD-fX >>